Fig. 6

Lower-dose CSF1R inhibition does not alter Aβ or Tau levels. a, b Sandwich ELISA in soluble and insoluble fraction revealed no significant differences in Aβ40 or Aβ42 between groups. c, d Thioflavin-S staining was performed, revealing plaques in both control and treated groups. Of the subiculum, 10× images are shown. e–g Analysis of plaques revealed no significant difference between treated and untreated brains in average number of plaques, average plaque size, or distribution of large, medium, and small plaques. h–k Immunostaining for total human tau with HT7 (h, i) and AT8 tau (j, k) reveals no significant differences in tau levels with PLX5622 treatment. Error bars indicate SEM